Pertuzumab-dpzb is now considered an interchangeable biosimilar to pertuzumab as part of treatment combinations in multiple HER2-positive breast cancer indications.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/first-pertuzumab-biosimilar-earns-fda-nod-breast-cancer-2025a1000vpu?src=rss
Author :
Publish date : 2025-11-14 11:44:00
Copyright for syndicated content belongs to the linked Source.
